Get the Stockscreener App
0.32
2.85%
-0.0094
Cyclacel Pharmaceuticals Inc stock is traded at $0.32, with a volume of 112.47K.
It is down -2.85% in the last 24 hours and down -22.08% over the past month.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
See More
Previous Close:
$0.3294
Open:
$0.33
24h Volume:
112.47K
Relative Volume:
0.04
Market Cap:
$3.71M
Revenue:
$74,000
Net Income/Loss:
$-13.43M
P/E Ratio:
-0.034
EPS:
-9.4
Net Cash Flow:
$-10.54M
1W Performance:
-3.90%
1M Performance:
-22.08%
6M Performance:
-78.45%
1Y Performance:
-86.27%
1-Day Range:
$0.3164
$0.33
1-Week Range:
$0.3129
$0.359
52-Week Range:
$0.3101
$4.00
Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile
Name
Cyclacel Pharmaceuticals Inc
Sector
Industry
Phone
908-517-7330
Address
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
Compare CYCC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYCC
Cyclacel Pharmaceuticals Inc
|
0.3186 | 3.71M | 74,000 | -13.43M | -10.54M | -9.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.33 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.00 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.48 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.98 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.61 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Apr-27-20 | Resumed | ROTH Capital | Buy |
| Sep-07-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-15 | Initiated | H.C. Wainwright | Buy |
| Feb-04-10 | Initiated | Roth Capital | Buy |
| Oct-28-09 | Initiated | Merriman | Buy |
| Aug-12-08 | Initiated | Piper Jaffray | Buy |
| Mar-12-08 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-12-08 | Reiterated | Collins Stewart | Buy |
| Mar-12-08 | Reiterated | Needham & Co | Buy |
| Nov-27-07 | Reiterated | Cantor Fitzgerald | Buy |
| Aug-10-07 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-04-07 | Reiterated | Needham & Co | Buy |
| Apr-23-07 | Initiated | Lazard Capital | Buy |
| Apr-10-07 | Initiated | Cantor Fitzgerald | Buy |
View All
Cyclacel Pharmaceuticals Inc Stock (CYCC) Latest News
Cyclacel Pharmaceuticals streamlines operations, plans asset purchase - MSN
Cyclacel Pharmaceuticals Announces Creditors Voluntary Liquidation Of UK Subsidiary - Marketscreener.com
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated at StockNews.com - Defense World
How To Trade (CYCCP) - Stock Traders Daily
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated by Analysts at StockNews.com - Defense World
(CYCCP) On The My Stocks Page - Stock Traders Daily
All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy - MSN
Cyclacel Pharmaceuticals Corrects Inadvertent Error in Securities Purchase Agreement - Defense World
How the (CYCCP) price action is used to our Advantage - Stock Traders Daily
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com - Defense World
Cyclacel Pharmaceuticals Announces Agreement for $3.1 Million Investment by David Lazar as Interim CEO - Defense World
Cyclacel Pharmaceuticals Restructures Leadership and Financial Strategy - TipRanks
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar - citybiz
Stock market news: Nauticus Robotics gained 93.71% while N2OFF rose by 128.03% during mid day trading - Business Upturn
Cyclacel Pharmaceuticals, Inc. Announces Chief Executive Officer Changes - Marketscreener.com
Why Cyclacel Pharmaceuticals (CYCC) Stock Is Skyrocketing - Benzinga
Cyclacel Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
Dow Jumps Over 100 Points; ISM Manufacturing PMI Increases In December - Benzinga
David Lazar acquires Cyclacel Pharmaceuticals preferred stock, becomes interim CEO; stock jumps - Seeking Alpha
Cyclacel Pharmaceuticals Secures $3.1M Investment, Names David Lazar as Interim CEO Amid Restructuring - StockTitan
Royal Bank of Canada (RY-T) QuotePress Release - The Globe and Mail
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
Trend Tracker for (CYCCP) - Stock Traders Daily
Cyclacel stock plunges to 52-week low, hits $0.32 - Investing.com India
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.com - Defense World
Stock Watch: A Biotech Holiday Horror Story - Citeline News & Insights
Cyclacel Pharmaceuticals Faces Potential Delisting from Nasdaq Stock Market Due to Minimum Bid Price Noncompliance - Defense World
Trading (CYCCP) With Integrated Risk Controls - Stock Traders Daily
Cash-strapped Cyclacel cuts costs as it searches for financial lifeline - Fierce Biotech
Cyclacel Pharmaceuticals Exploring Alternatives, Cuts Costs to Preserve Cash - MarketWatch
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs - The Manila Times
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of - EIN News
Cyclacel Pharmaceuticals Seeks Urgent Strategic Options Amid Nasdaq Delisting Risk - StockTitan
Li Auto Inc ADR (LI-Q) QuotePress Release - The Globe and Mail
Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $2.062112 million in funding - Marketscreener.com
Cyclacel Pharmaceuticals, Inc. announced that it has received $2.062112 million in funding - Marketscreener.com
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Cyclacel stock plunges to 52-week low of $0.32 amid market challenges By Investing.com - Investing.com South Africa
Cyclacel stock plunges to 52-week low of $0.32 amid market challenges - Investing.com
Cyclacel Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks
Cyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds - The Manila Times
Armistice Capital, LLC Increases Stake in Cyclacel Pharmaceutica - GuruFocus.com
Cyclacel Pharmaceuticals Raises $2.1M Through Warrant Exercise at $0.415 Per Share | CYCC Stock News - StockTitan
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss - MSN
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds - The Manila Times
Cyclacel stock plunges to 52-week low of $0.37 amid market challenges - Investing.com Canada
Cyclacel Pharmaceuticals Raises $2.1M Through Warrant Exercise Deal at $0.415 Per Share | CYCC Stock News - StockTitan
Cyclacel Pharmaceuticals appoints new auditor By Investing.com - Investing.com Australia
Cyclacel Pharmaceuticals Inc Stock (CYCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):